GLP-1 analog fusion proteins

Details for Australian Patent Application No. 2004251145 (hide)

Owner Eli Lilly and Company

Inventors Millican, Rohn Lee. Jr.; Glaesner, Wolfgang; Vick, Andrew Mark

Agent Spruson & Ferguson

Pub. Number AU-B-2004251145

PCT Pub. Number WO2005/000892

Priority 60/477,880 12.06.03 US

Filing date 10 June 2004

Wipo publication date 6 January 2005

Acceptance publication date 9 September 2010

International Classifications

C07K 14/605 (2006.01) Peptides having more than 20 amino acids

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07K 14/50 (2006.01) Peptides having more than 20 amino acids

A61K 38/00 (2006.01) Medicinal preparations containing peptides

Event Publications

24 November 2005 PCT application entered the National Phase

  PCT publication WO2005/000892 Priority application(s): WO2005/000892

1 December 2005 Amendment Made

  The nature of the amendment is: Amend the invention title to read GLP-1 analog fusion proteins

9 September 2010 Application Accepted

  Published as AU-B-2004251145

23 December 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 01 Dec 2010. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

14 April 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 01 Dec 2010

21 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004251146-Immunosuppressant compounds and compositions

2004251144-Low temperature liquid polythioether polymers